166 related articles for article (PubMed ID: 33277750)
1. α-Emitting cancer therapy using
Kaneda-Nakashima K; Zhang Z; Manabe Y; Shimoyama A; Kabayama K; Watabe T; Kanai Y; Ooe K; Toyoshima A; Shirakami Y; Yoshimura T; Fukuda M; Hatazawa J; Nakano T; Fukase K; Shinohara A
Cancer Sci; 2021 Mar; 112(3):1132-1140. PubMed ID: 33277750
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[
Ohshima Y; Suzuki H; Hanaoka H; Sasaki I; Watanabe S; Haba H; Arano Y; Tsushima Y; Ishioka NS
Nucl Med Biol; 2020; 90-91():15-22. PubMed ID: 32916470
[TBL] [Abstract][Full Text] [Related]
3. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
4. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
Kanai Y
Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
[TBL] [Abstract][Full Text] [Related]
5. Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2.
Aoki M; Watabe T; Nagamori S; Naka S; Ikeda H; Kongpracha P; Horitsugi G; Kanai Y; Shimosegawa E; Kanai Y; Hatazawa J
Ann Nucl Med; 2019 Jun; 33(6):394-403. PubMed ID: 30820863
[TBL] [Abstract][Full Text] [Related]
6. Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B.
Li HK; Hasegawa S; Nakajima NI; Morokoshi Y; Minegishi K; Nagatsu K
Biochem Biophys Res Commun; 2018 Dec; 506(4):1078-1084. PubMed ID: 30409432
[TBL] [Abstract][Full Text] [Related]
7. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T
Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.
Ueda S; Hayashi H; Miyamoto T; Abe S; Hirai K; Matsukura K; Yagi H; Hara Y; Yoshida K; Okazaki S; Tamura M; Abe Y; Agatsuma T; Niwa SI; Masuko K; Masuko T
Cancer Sci; 2019 Feb; 110(2):674-685. PubMed ID: 30548114
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy.
Li L; Di X; Wu M; Sun Z; Zhong L; Wang Y; Fu Q; Kan Q; Sun J; He Z
Nanomedicine; 2017 Apr; 13(3):987-998. PubMed ID: 27890657
[TBL] [Abstract][Full Text] [Related]
10. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
11. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
Bhunia S; Vangala V; Bhattacharya D; Ravuri HG; Kuncha M; Chakravarty S; Sistla R; Chaudhuri A
Mol Pharm; 2017 Nov; 14(11):3834-3847. PubMed ID: 28958145
[TBL] [Abstract][Full Text] [Related]
12. Novel
Hanaoka H; Ohshima Y; Yamaguchi A; Suzuki H; Ishioka NS; Higuchi T; Arano Y; Tsushima Y
Mol Pharm; 2019 Aug; 16(8):3609-3616. PubMed ID: 31242385
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB
Wang Z; Chi D; Wu X; Wang Y; Lin X; Xu Z; Liu H; Sun J; He Z; Wang Y
J Control Release; 2019 Dec; 316():22-33. PubMed ID: 31676386
[TBL] [Abstract][Full Text] [Related]
14. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.
Makvandi M; Lieberman BP; LeGeyt B; Hou C; Mankoff DA; Mach RH; Pryma DA
Nucl Med Biol; 2016 Jan; 43(1):35-41. PubMed ID: 26702785
[TBL] [Abstract][Full Text] [Related]
15. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
16. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
17. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
Rautio J; Kärkkäinen J; Huttunen KM; Gynther M
Eur J Pharm Sci; 2015 Jan; 66():36-40. PubMed ID: 25305508
[TBL] [Abstract][Full Text] [Related]
18. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
20. The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells.
Kim CH; Park KJ; Park JR; Kanai Y; Endou H; Park JC; Kim DK
Anticancer Res; 2006; 26(4B):2943-8. PubMed ID: 16886618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
